ClinicalTrials.gg
Not yet recruitingNCT07278908Updated Dec 12, 2025

Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia

A Phase 2/3 interventional study of Avatrombopag+All trans retinoic acid and Avatrombopag in ITP - Immune Thrombocytopenia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Planned enrollment
Largest of 16
248 · median 53
Started
2025
with 2 others
Phase 2/3
Only one
of the 16
Registered
16th of 16
by date
Lead sponsor
3 of 16
Institute of Hematology & Blood Diseases Hospital, China

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one has the largest planned enrollment, is one of 3 that started in 2025, is the only one in phase 2/3, and was the 16th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

This study is an open label, randomized controlled, multicenter clinical trial aimed at comparing the efficacy and safety of the combination of atorvastatin and all trans retinoic acid with atorvastatin alone in the treatment of first-line ineffective or recurrent immune thrombocytopenia.

The study is divided into a screening period (2 weeks), a treatment period (0-24 weeks), a reduction period (25-36 weeks), and a follow-up period (37-52 weeks), with a total of one year from the start of treatment to the end of follow-up (52 weeks).

03

Conditions studied

  • ITP - Immune Thrombocytopenia

Keywords

  • Immune Thrombocytopenia
  • all trans retinoic acid
  • Avatrombopag
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient signs an form;
  2. ≥ 18 years old;
  3. The patient's history of ITP is at least 3 months (persistent or chronic ITP);
  4. The count of the subject within 24 hours before the first administration of the study drug is less than 30 × 10\^9/L; during the screening period, platelet count is measured at least twice (at least 1 week apart), with an average platelet count of less than 30 × 10\^9/L and no platelet count greater than 35 × 10\^9/L;
  5. treatment, such as ineffective hormone or immunoglobulin therapy, or ITP patients who relapse after treatment;
  6. Receive concomitant therapy drugs (including stable doses of within the past month, stable doses of azathioprine, danazol, cyclosporine A, or mycophenolate mofetil within the past three months) for treatment; TPO receptor agonists should be discontinued at least 2 weeks before enrollment; Patients receiving anti-CD20 treatment should discontinue the medication six months prior to enrollment; Patients who underwent splenectomy were enrolled six months after the completion of the surgery;
  7. Within the past year, there have been no heart diseases, including class III/IV congestive heart failure, drug-induced arrhythmias, or myocardial infarction;
  8. Laboratory tests of coagulation function showed that the (PT/INR) and activated partial thromboplastin time (APTT) values did not exceed 20% of the normal reference range; No history of coagulation abnormalities except for ITP;
  9. White blood cell count, , and are within the normal range in the laboratory, with no abnormalities other than ITP, except for the following situations: a) Hemoglobin: If the anemia is clearly caused by iron deficiency anemia (excessive loss of blood related to thrombocytopenia) due to ITP, the subject's hemoglobin level below the lower limit of normal values can be selected for the study based on the researcher's judgment; c) Absolute neutrophil count ≥ 1.5 × 10\^9/L can be included in the group;
  10. The main organ function is good, that is, the liver and kidney function is good before treatment, and ALT are ≤ 1.5 times the (ULN), total is ≤ 1.5 times ULN, and serum creatinine is ≤ 1.5 times ULN;
  11. The subjects adopted approved methods. Female participants must be infertile (hysterectomy, bilateral salpingectomy, bilateral tubal ligation, or more than 1 year after menopause) or have the ability to conceive but have used study approved contraceptive methods during the entire study period until the end of the follow-up period, 2 weeks before the first dose; Women with fertility must have a negative serum pregnancy test within 24 hours prior to the first dose of medication;
  12. The subjects fully understand and are able to comply with the requirements of the research protocol, and are willing to complete the study as planned.

Exclusion criteria

Exclusion Criteria:

  1. Individuals who are allergic to known ingredients or in atorvastatin or all trans retinoic acid;
  2. Accept medication maintenance therapy (including but not limited to aspirin, clopidogrel, and/or nonsteroidal anti-inflammatory drugs NSAIDs) or anticoagulants that affect function or quantity;
  3. Accompanied by hemolytic anemia, or various secondary or hereditary thrombocytopenia; Such as leukemia, lymphoma, multiple myeloma, aplastic anemia, myelodysplastic syndrome, Evans syndrome, common variant immunodeficiency, systemic lupus erythematosus, cirrhosis, antiphospholipid antibody syndrome, pseudothrombocytopenia, drug-induced thrombocytopenia (such as quinine, heparin, antimicrobial drugs, antiepileptic drugs, etc.), etc;
  4. There is bone marrow fibrosis with MF ≥ 2;
  5. Participate in other research drug studies (including vaccine studies) or be exposed to other research drugs (TPO receptor agonists or salvage treatments) within 4 weeks or 5 half lives (whichever is longer) before the first use of the medication;
  6. Previous ITP treatments, including rescue therapy with platelet transfusions, , immunoglobulins, immunomodulators, etc., did not end within 2 weeks prior to enrollment;
  7. The subject has a history of any arterial/venous thrombosis (including stroke, , myocardial infarction, deep vein thrombosis, or pulmonary embolism) within the past year;
  8. Pregnant or lactating women;
  9. History of alcohol/drug abuse within 12 months prior to screening or first dose;
  10. Previous studies have shown poor efficacy in the treatment of sufficient and sufficient doses of atorvastatin;
  11. Previous all trans retinoic acid had poor efficacy;
  12. All laboratory or clinical evidence of infection and active hepatitis during screening. Laboratory tests during the screening period indicate active infection or infection. (hepatitis B reference: HBsAg positive and HBV DNA ≥ 500 IU/ml; Hepatitis C reference: HCV antibody positive and HCV virus copy number>);
  13. Life threatening bleeding (WHO bleeding score 3) or estimated need for salvage treatment before the first dose of treatment in patients;
  14. History of malignant tumors or accompanying malignant tumors;
  15. The researchers believe that there are any other circumstances that may prevent the subjects from completing the study or pose significant risks to them.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Avatrombopag+All trans retinoic acid

    Drug: Avatrombopag+All trans retinoic acid

  • Active comparator
    Avatrombopag

    Drug: Avatrombopag

Interventions

  • DrugAvatrombopag+All trans retinoic acid

    Drug pages: AvatrombopagStudies of AvatrombopagAvatrombopag pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TretinoinStudies of TretinoinTretinoin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Avatrombopag, po, starting dose 20mg qd, later adjusted dose or frequency according to response; All trans retinoic acid, po, 10mg bid.

  • Avatrombopag, po, starting dose 20mg qd, later adjusted dose or frequency according to response

06

What researchers measure

Primary outcomes

  1. Treatment Free Rate at week 52

    Time frame: up to 52 weeks

Secondary outcomes

  1. At weeks 12 and 24 without rescue treatment, the proportion of subjects with platelet levels reaching CR, R, and ≥ 50 × 10^9/L, respectively

    Time frame: up to 12 and 24 weeks

  2. Treatment Free Rate at week 12 after discontinuation of treatment

    Time frame: up to 12 weeks after discontinuation of treatment

  3. The proportion of subjects whose platelet levels reached CR and R at 12 weeks after discontinuation of treatment

    Time frame: up to 12 weeks after discontinuation of treatment

  4. The time from the start of treatment to the first platelet count ≥ 50 × 10^9/L

    From date of randomization until the date of first documented platelet count ≥ 50 × 10\^9/L, assessed up to 52 weeks

    Time frame: up to 52 weeks

  5. The time required from the start of treatment to the first platelet count increasing by at least 2 times compared to the baseline platelet count

    From date of randomization until the date of first documented platelet count increasing by at least 2 times compared to the baseline platelet count, assessed up to 52 weeks

    Time frame: up to 52 weeks

  6. The number of times subjects received rescue therapy during treatment and follow-up, and the proportion of subjects who received at least one rescue therapy

    Time frame: up to 52 weeks

  7. World Health Organization(WHO) bleeding scoring criteria

    score range: 0-4; higher scores mean a worse outcome

    Time frame: up to 52 weeks

  8. The Functional Assessment ot Chronic Illness Therapy-Fatigure(FACITF) score

    score range: 0-52; higher scores mean a worse outcome

    Time frame: up to 52 weeks

  9. Adverse event

    Time frame: up to 52 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 12, 2025
StartEst.
Dec 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07278908
Responsible party
Sponsor
First posted
Dec 12, 2025
Start date
Dec 2025 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Avatrombopag · Tretinoin

Start the discussion